Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Decnupaz (pivekimab sunirine-pvzy)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

DNA replication inhibitor, CD123-targeted antibody-drug conjugate

Related drugs:

‹

›

CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	pivekimab sunirine-pvzy Sensitive: C2 – Inclusion Criteria pivekimab sunirine-pvzy Sensitive : C2	pivekimab sunirine-pvzy Sensitive: C2 – Inclusion Criteria pivekimab sunirine-pvzy Sensitive : C2
CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	venetoclax + pivekimab sunirine-pvzy Sensitive: C2 – Inclusion Criteria venetoclax + pivekimab sunirine-pvzy Sensitive : C2	venetoclax + pivekimab sunirine-pvzy Sensitive: C2 – Inclusion Criteria venetoclax + pivekimab sunirine-pvzy Sensitive : C2
IL3RA positive	Acute Myelogenous Leukemia	IL3RA positive	Acute Myelogenous Leukemia	pivekimab sunirine-pvzy Sensitive: C2 – Inclusion Criteria pivekimab sunirine-pvzy Sensitive : C2	pivekimab sunirine-pvzy Sensitive: C2 – Inclusion Criteria pivekimab sunirine-pvzy Sensitive : C2
IL3RA expression	Childhood B Acute Lymphoblastic Leukemia	IL3RA expression	Childhood B Acute Lymphoblastic Leukemia	pivekimab sunirine-pvzy Sensitive: D – Preclinical pivekimab sunirine-pvzy Sensitive : D	pivekimab sunirine-pvzy Sensitive: D – Preclinical pivekimab sunirine-pvzy Sensitive : D